• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

REIMAGINE 前列腺癌筛查研究更新 NCT04063566：使用磁共振成像邀请男性进行前列腺癌筛查。

Update from the ReIMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging.

机构信息

UCL Division of Surgical & Interventional Sciences, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.

UCL Division of Surgical & Interventional Sciences, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.

出版信息

Eur Urol Focus. 2021 May;7(3):503-505. doi: 10.1016/j.euf.2021.03.027. Epub 2021 Apr 23.

DOI:10.1016/j.euf.2021.03.027
PMID:33896710
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7614671/
Abstract

ReIMAGINE Screening is a single-centre study assessing the feasibility of biparametric magnetic resonance imaging as a screening tool for prostate cancer. The study outcomes will take us a step towards more accurate and less harmful prostate cancer screening.

摘要

ReIMAGINE 筛查是一项单中心研究，旨在评估双参数磁共振成像作为前列腺癌筛查工具的可行性。该研究结果将使我们朝着更准确、危害更小的前列腺癌筛查迈进。

相似文献

1
Update from the ReIMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging.REIMAGINE 前列腺癌筛查研究更新 NCT04063566：使用磁共振成像邀请男性进行前列腺癌筛查。
Eur Urol Focus. 2021 May;7(3):503-505. doi: 10.1016/j.euf.2021.03.027. Epub 2021 Apr 23.
2
ReIMAGINE Prostate Cancer Screening Study: protocol for a single-centre feasibility study inviting men for prostate cancer screening using MRI.ReIMAGINE 前列腺癌筛查研究：一项单中心可行性研究的方案，邀请男性使用 MRI 进行前列腺癌筛查。
BMJ Open. 2021 Sep 30;11(9):e048144. doi: 10.1136/bmjopen-2020-048144.
3
Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING).双参数磁共振成像（VISIONING）用于机会性前列腺癌筛查
Eur Urol Focus. 2024 Mar;10(2):332-338. doi: 10.1016/j.euf.2024.02.006. Epub 2024 Feb 23.
4
Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.经活检初筛的男性中，使用双参数磁共振成像联合前列腺特异性抗原密度检测和排除 Gleason7-10 前列腺癌。
Eur Urol Oncol. 2019 May;2(3):311-319. doi: 10.1016/j.euo.2018.09.001. Epub 2018 Sep 27.
5
Beyond the : Biparametric MRI-Based Prostate Cancer Screening-A Cost-Effective Alternative to PSA Screening and Standard Biopsy.超越：基于双参数磁共振成像的前列腺癌筛查——一种比前列腺特异性抗原筛查和标准活检更具成本效益的替代方法。
AJR Am J Roentgenol. 2023 Sep;221(3):389. doi: 10.2214/AJR.23.29011. Epub 2023 Jan 18.
6
Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.45 岁时前列腺癌筛查的多参数磁共振成像：PROBASE 试验首轮筛查结果。
Eur Urol. 2024 Feb;85(2):105-111. doi: 10.1016/j.eururo.2023.09.027. Epub 2023 Oct 18.
7
Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.磁共振成像在前列腺癌筛查中的作用：哥德堡随机筛查试验中的一项试点研究
Eur Urol. 2016 Oct;70(4):566-573. doi: 10.1016/j.eururo.2015.12.006. Epub 2015 Dec 24.
8
Usefulness of Biparametric Magnetic Resonance Imaging Combined With Prostate Specific Antigen Density in Pre-biopsy Detection of Clinically Insignificant Prostate Cancer.在临床无意义前列腺癌的活检前检测中，双参数磁共振成像联合前列腺特异性抗原密度的应用价值。
Anticancer Res. 2021 Apr;41(4):2183-2186. doi: 10.21873/anticanres.14992.
9
Men's Acceptance of Screening for Prostate Cancer with Prostate-specific Antigen, Magnetic Resonance Imaging, and Prostate Biopsy.男性对前列腺特异性抗原、磁共振成像和前列腺活检筛查前列腺癌的接受度。
Eur Urol Oncol. 2024 Jun;7(3):553-562. doi: 10.1016/j.euo.2023.11.003. Epub 2023 Nov 22.
10
Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial-Prostate Cancer Secondary Screening in Sapienza (PROSA).基于磁共振成像的前列腺癌早期诊断筛查方案设计：一项随机对照试验的初步结果——萨皮恩扎大学（PROSA）前列腺癌二级筛查。
Eur Radiol. 2024 Jan;34(1):204-213. doi: 10.1007/s00330-023-10019-1. Epub 2023 Aug 10.

引用本文的文献

1
Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer : A Decision Model Analysis.基于双参数磁共振成像的前列腺癌一线筛查的终生健康和经济结局：决策模型分析。
Ann Intern Med. 2024 Jul;177(7):871-881. doi: 10.7326/M23-1504. Epub 2024 Jun 4.
2
Diagnostic Accuracy of Abbreviated Bi-Parametric MRI (a-bpMRI) for Prostate Cancer Detection and Screening: A Multi-Reader Study.简化双参数磁共振成像（a-bpMRI）用于前列腺癌检测和筛查的诊断准确性：一项多阅片者研究
Diagnostics (Basel). 2022 Jan 18;12(2):231. doi: 10.3390/diagnostics12020231.
3
The ReIMAGINE Multimodal Warehouse: Using Artificial Intelligence for Accurate Risk Stratification of Prostate Cancer.重新构想多模式仓库：利用人工智能对前列腺癌进行准确的风险分层。
Front Artif Intell. 2021 Nov 16;4:769582. doi: 10.3389/frai.2021.769582. eCollection 2021.

本文引用的文献

1
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.欧洲前列腺癌筛查随机研究的 16 年随访。
Eur Urol. 2019 Jul;76(1):43-51. doi: 10.1016/j.eururo.2019.02.009. Epub 2019 Feb 26.
2
Simplified Luminal Water Imaging for the Detection of Prostate Cancer From Multiecho T MR Images.基于多回波 T1 加权磁共振成像的简化管腔水成像检测前列腺癌。
J Magn Reson Imaging. 2019 Sep;50(3):910-917. doi: 10.1002/jmri.26608. Epub 2018 Dec 19.
3
Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.基于低强度前列腺特异性抗原的筛查干预对前列腺癌死亡率的影响：CAP随机临床试验
JAMA. 2018 Mar 6;319(9):883-895. doi: 10.1001/jama.2018.0154.
4
Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.哥德堡基于人群的前列腺癌随机筛查试验的18年随访：社会人口统计学变量对参与率、前列腺癌发病率和死亡率的影响。
Scand J Urol. 2018 Feb;52(1):27-37. doi: 10.1080/21681805.2017.1411392. Epub 2017 Dec 18.
5
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.多参数 MRI 和 TRUS 活检在前列腺癌（PROMIS）中的诊断准确性：一项配对验证性研究。
Lancet. 2017 Feb 25;389(10071):815-822. doi: 10.1016/S0140-6736(16)32401-1. Epub 2017 Jan 20.
6
Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.PLCO试验中前列腺癌筛查的延长死亡率结果，中位随访时间为15年。
Cancer. 2017 Feb 15;123(4):592-599. doi: 10.1002/cncr.30474. Epub 2016 Dec 1.
7
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.前列腺特异性抗原与前列腺癌：预测、检测及监测
Nat Rev Cancer. 2008 Apr;8(4):268-78. doi: 10.1038/nrc2351.
8
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.前列腺特异性抗原水平≤4.0纳克/毫升的男性中前列腺癌的患病率。
N Engl J Med. 2004 May 27;350(22):2239-46. doi: 10.1056/NEJMoa031918.